Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
National Institutes of Health · Howard Hughes Medical Institute · +1 more institution
Abstract
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%),…
Citation impact
- FWCI
- 30.41
- Percentile
- 100%
- References
- 38
Authors
17- GQGiao Q. PhanCorresponding
National Institutes of Health, Howard Hughes Medical Institute, National Cancer Institute
- JCJames Chih‐Hsin Yang
National Institutes of Health, Howard Hughes Medical Institute, National Cancer Institute
- RMRichard M. Sherry
National Institutes of Health, Howard Hughes Medical Institute, National Cancer Institute
- PHPatrick Hwu
National Institutes of Health, Howard Hughes Medical Institute, National Cancer Institute
- SLSuzanne L. Topalian
National Institutes of Health, Howard Hughes Medical Institute, National Cancer Institute
Topics & keywords
- Cytotoxic T cell
- Immunology
- Antigen
- Melanoma
- Cancer immunotherapy
- Blockade
- Immunotherapy
- Medicine
- Good health and well-being